search
Back to results

Investigation and Validation of a Study Project on Digital Therapy Management of Patients With Arterial Hypertension (eXPLORE)

Primary Purpose

Cardiovascular Diseases, Hypertension

Status
Recruiting
Phase
Not Applicable
Locations
Germany
Study Type
Interventional
Intervention
Hypertension therapy through iATROS medical device
Sponsored by
iATROS GmbH
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Cardiovascular Diseases focused on measuring eHealth, cardiology, hypertension

Eligibility Criteria

18 Years - 100 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • ≥ 18 years of age
  • Existing diagnosis of arterial hypertension according to ICD-10 I10.- to I13.-, i.e. presence of the disease is recorded at the time of inclusion in the study.
  • Blood pressure at the time of inclusion is ≥130 mmHg systolic (24h mean) resp. ≥80 mmHg diastolic (24h mean) at 24h blood pressure measurement.
  • Possession and use of a smartphone that allows the installation and use of "iATROS", whereby "use" implies that the patient possesses the physical and mental abilities to use and apply the iATROS app

Exclusion Criteria:

  • Lack of capacity to consent
  • < 18 years of age or ≥ 90 years of age
  • No use of a smartphone
  • Lack of the physical and mental abilities necessary to use the iATROS app, or generally to use so-called "apps" on a smartphone or tablet.
  • Tumor disease associated with a reduced life expectancy of less than 1 year
  • Immunosuppression
  • Advanced dementia
  • Any other disease associated with a reduced life expectancy of less than 1 year
  • Any disease/condition that limits participation in the program
  • Pregnant or breastfeeding patients
  • A secondary hypertension known to the patient (by history)
  • Blood pressure at inclusion is >170mmHg systolic on 24h blood pressure measurement (24h mean).
  • Existing participation and enrollment in the iATROS hypertension health program.
  • Participation in another clinical trial, if complications with compliance, the measures to be performed, a distortion of the results, or the status of a treatment according to the current standard of care result from the participation.
  • Comorbidities or the presence of any other physical condition that would prohibit the use of the ESC Hypertension Guideline of 2018 as target blood pressure (i.e. if, due to the patient's individual situation, a different value should be given as a target value for a blood pressure value to be classified as healthy).
  • Addictions
  • Stroke in the last 3 months
  • Transient ischemic attack (TIA) in the last 3 months

Sites / Locations

  • Medizinische Klinik und Poliklinik 1, Ludwig-Maximilians-University of MunichRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

Intervention Group

Control Group

Arm Description

The intervention to be carried out in the treatment group is the use of the therapy measures for the treatment of arterial hypertension, which is delivered through the iATROS medical device. The therapy by means of the medical device takes place over 90 days.

For the duration of the in-life phase, the treatment of the control group will follow the standard-of-care except for the measures necessary for the conduct of the study.

Outcomes

Primary Outcome Measures

Exploratory testing of study-related measures and the use of iATROS.
Determination of subjective burden perception of the study-related measures using the Study Participant Feedback Questionnaire (SPFQ) - Questionnaire. The three subscales (A-C) are administered at three discrete time points, immediately after enrolment, after half the in-live phase time has passed and at the last visit in the study center. The questions are answered on a 5-point scale with a higher level indicating a higher satisfaction with the study-related measures. Possible levels are 0 to 24 (subscale A), 0 to 39 (subscale B) and 0 to 14 (subscale C).

Secondary Outcome Measures

Blood pressure reduction
Measurement of blood pressure in mmHg after 90 days of treatment as compared to baseline. Comparison of the mean absolute reduction in systolic blood pressure in intragroup analysis per study arm and between treatment arms (intervention vs. control).
Blood pressure classification
Assessment of the fraction of patients in [%] with a blood pressure classified as "healthy" as per the definition outlined in the "2018 ESC/ESH Clinical Practice Guidelines for the Management of Arterial Hypertension " after 90 days of treatment and at follow-up at 180 days as compared to baseline. Comparison of the mean absolute reduction in systolic blood pressure in intragroup analysis per study arm and between treatment arms (intervention vs. control).
Health Literacy Questionnaire (HLQ)
Administration of the Health Literacy Questionnaire (HLQ) to assess disease-related health literacy. The questionnaire is comprised of 9 subscales. Scale 1-5 are graded on a 4-point scale (possible levels per subscale 1 to 4), scale 6-9 are graded on a 5-point scale (possible levels per subscale 1 to 5) with higher levels showing higher health literacy. Measurement at baseline and at the end of a 90-day treatment period. Assessment of changes in health literacy in intra-group comparison per study arm and inter-group comparison.
Patient Activation Measure (PAM)
Measurement of degree of patient activation via the Patient Activation Measure (PAM) questionnaire. Measurement at baseline and at the end of a 90-day treatment period. Assessment of changes in health literacy in intra-group comparison per study arm and inter-group comparison. Possible levels 0 to 100, with a higher level indicating higher activation.
Blood pressure reduction effect stability
Measurement of blood pressure level in mmHg 90 days after finishing in-live phase and comparison to blood pressure level 90 days after enrolment. Comparison of the mean absolute reduction in systolic blood pressure in intragroup analysis per study arm and between treatment arms (intervention vs. control).

Full Information

First Posted
October 11, 2022
Last Updated
October 18, 2023
Sponsor
iATROS GmbH
search

1. Study Identification

Unique Protocol Identification Number
NCT05580068
Brief Title
Investigation and Validation of a Study Project on Digital Therapy Management of Patients With Arterial Hypertension
Acronym
eXPLORE
Official Title
Pilot-Studie Zur Explorativen Untersuchung Und Validierung Eines Studienvorhabens Zur Digitalen Therapiesteuerung Von Patienten Mit Arterieller Hypertonie im Vergleich Der Behandlung Mit Dem Standard-of-Care - iATROS eXPLORE
Study Type
Interventional

2. Study Status

Record Verification Date
February 2023
Overall Recruitment Status
Recruiting
Study Start Date
November 10, 2022 (Actual)
Primary Completion Date
May 2024 (Anticipated)
Study Completion Date
May 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
iATROS GmbH

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this pilot study is to exploratively test the basic feasibility of a clinical trial for the controlled investigation of the efficacy and effectiveness of iATROS digital therapy management in the treatment of patients with arterial hypertension within the framework of a clinical trial. In addition, the results of the treatment will be used to generate an initial data basis for the effectiveness of treatment with iATROS.
Detailed Description
The aim of this pilot project is to form the basis for testing the iATROS platform in an controlled setting of a clinical study, in particular to collect data for a more precise determination of the sample size including the investigation of dropout rates, to investigate the acceptance of study-related measures, and to test and better prepare the procedures for the successful implementation of study-related measures. Furthermore, the first data for testing the effectiveness of the iATROS solution for the treatment of hypertensive patients will be collected. For this purpose, health data as well as data points on health literacy and patient sovereignty will be collected from the patients in the pilot study.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cardiovascular Diseases, Hypertension
Keywords
eHealth, cardiology, hypertension

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
monocentric randomized controlled study (RCT)
Masking
None (Open Label)
Allocation
Randomized
Enrollment
100 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Intervention Group
Arm Type
Experimental
Arm Description
The intervention to be carried out in the treatment group is the use of the therapy measures for the treatment of arterial hypertension, which is delivered through the iATROS medical device. The therapy by means of the medical device takes place over 90 days.
Arm Title
Control Group
Arm Type
No Intervention
Arm Description
For the duration of the in-life phase, the treatment of the control group will follow the standard-of-care except for the measures necessary for the conduct of the study.
Intervention Type
Device
Intervention Name(s)
Hypertension therapy through iATROS medical device
Intervention Description
The intervention to be carried out in the treatment group is the use of the therapy support provided by the iATROS medical device for the treatment of arterial hypertension. In particular, patients are guided through a structured digital therapy program that enables them to better manage their disease. Patient receive reminders for taking their medication, for performing vital parameter measurements, and receive educational content for them to learn how to manage their disease better.
Primary Outcome Measure Information:
Title
Exploratory testing of study-related measures and the use of iATROS.
Description
Determination of subjective burden perception of the study-related measures using the Study Participant Feedback Questionnaire (SPFQ) - Questionnaire. The three subscales (A-C) are administered at three discrete time points, immediately after enrolment, after half the in-live phase time has passed and at the last visit in the study center. The questions are answered on a 5-point scale with a higher level indicating a higher satisfaction with the study-related measures. Possible levels are 0 to 24 (subscale A), 0 to 39 (subscale B) and 0 to 14 (subscale C).
Time Frame
Baseline and study completion, an average of 180 days
Secondary Outcome Measure Information:
Title
Blood pressure reduction
Description
Measurement of blood pressure in mmHg after 90 days of treatment as compared to baseline. Comparison of the mean absolute reduction in systolic blood pressure in intragroup analysis per study arm and between treatment arms (intervention vs. control).
Time Frame
Baseline and 90 days after enrolment
Title
Blood pressure classification
Description
Assessment of the fraction of patients in [%] with a blood pressure classified as "healthy" as per the definition outlined in the "2018 ESC/ESH Clinical Practice Guidelines for the Management of Arterial Hypertension " after 90 days of treatment and at follow-up at 180 days as compared to baseline. Comparison of the mean absolute reduction in systolic blood pressure in intragroup analysis per study arm and between treatment arms (intervention vs. control).
Time Frame
Baseline, 90 days, and 180 days after enrolment
Title
Health Literacy Questionnaire (HLQ)
Description
Administration of the Health Literacy Questionnaire (HLQ) to assess disease-related health literacy. The questionnaire is comprised of 9 subscales. Scale 1-5 are graded on a 4-point scale (possible levels per subscale 1 to 4), scale 6-9 are graded on a 5-point scale (possible levels per subscale 1 to 5) with higher levels showing higher health literacy. Measurement at baseline and at the end of a 90-day treatment period. Assessment of changes in health literacy in intra-group comparison per study arm and inter-group comparison.
Time Frame
Baseline and 90 days after enrolment
Title
Patient Activation Measure (PAM)
Description
Measurement of degree of patient activation via the Patient Activation Measure (PAM) questionnaire. Measurement at baseline and at the end of a 90-day treatment period. Assessment of changes in health literacy in intra-group comparison per study arm and inter-group comparison. Possible levels 0 to 100, with a higher level indicating higher activation.
Time Frame
Baseline and 90 days after enrolment
Title
Blood pressure reduction effect stability
Description
Measurement of blood pressure level in mmHg 90 days after finishing in-live phase and comparison to blood pressure level 90 days after enrolment. Comparison of the mean absolute reduction in systolic blood pressure in intragroup analysis per study arm and between treatment arms (intervention vs. control).
Time Frame
90 days and 180 days after enrolment

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
100 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: ≥ 18 years of age Existing diagnosis of arterial hypertension according to ICD-10 I10.- to I13.-, i.e. presence of the disease is recorded at the time of inclusion in the study. Blood pressure at the time of inclusion is ≥130 mmHg systolic (24h mean) at 24h blood pressure measurement or, alternatively, at-home blood pressure measurement at ≥135 mmHg systolic (mean of 7 days). In case of the presence of a 24-h blood pressure measurement, this value is decisive compared to the at-home measurement. Possession and use of a smartphone that allows the installation and use of "iATROS", whereby "use" implies that the patient possesses the physical and mental abilities to use and apply the iATROS app Exclusion Criteria: Lack of capacity to consent < 18 years of age No use of a smartphone Lack of the physical and mental abilities necessary to use the iATROS app, or generally to use so-called "apps" on a smartphone or tablet. Tumor disease associated with a reduced life expectancy of less than 1 year Immunosuppression Advanced dementia Any other disease associated with a reduced life expectancy of less than 1 year Any disease/condition that limits participation in the program Pregnant or breastfeeding patients A secondary hypertension known to the patient (by history) Blood pressure at inclusion is >170mmHg systolic on 24h blood pressure measurement (24h mean) or, alternatively, the at-home blood pressure measurement is >175mmHg systolic (mean value of the 7 days). In case of a 24h blood pressure measurement, this value is decisive compared to the at-home measurement. Existing participation and enrollment in the iATROS hypertension health program. Participation in another clinical trial, if complications with compliance, the measures to be performed, a distortion of the results, or the status of a treatment according to the current standard of care result from the participation. Comorbidities or the presence of any other physical condition that would prohibit the use of the ESC Hypertension Guideline of 2018 as target blood pressure (i.e. if, due to the patient's individual situation, a different value should be given as a target value for a blood pressure value to be classified as healthy). Addictions Stroke in the last 3 months Transient ischemic attack (TIA) in the last 3 months
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Paul Weyh
Phone
+49 176 856 23 142
Email
paul.weyh@i-atros.com
First Name & Middle Initial & Last Name or Official Title & Degree
Georges von Degenfeld, Dr. med.
Phone
+49 89 - 95879243
Email
georges.degenfeld@i-atros.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Stefan Brunner, Prof. Dr.
Organizational Affiliation
Medizinische Klinik und Poliklinik 1, Ludwig-Maximilians-University of Munich
Official's Role
Principal Investigator
Facility Information:
Facility Name
Medizinische Klinik und Poliklinik 1, Ludwig-Maximilians-University of Munich
City
Munich
State/Province
Bavaria
ZIP/Postal Code
80336
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Stefan Brunner, Prof. Dr.
Email
Stefan.Brunner@med.uni-muenchen.de
First Name & Middle Initial & Last Name & Degree
Monika Baylacher
Phone
+49 89 4400 57670
Email
monika.baylacher@med.uni-muenchen.de

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Investigation and Validation of a Study Project on Digital Therapy Management of Patients With Arterial Hypertension

We'll reach out to this number within 24 hrs